Identify the most effective dose of valproic acid when used in combination with phenytoin for
treatment of patients with refractory status epilepticus, which allow a better clinical
course and prognosis of the disease.
Drug: valproic acid (VPA)
We will connect you to the doctor responsible for this trial and help you get more information.
Locations near you
Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Full eligibility criteria for NCT01586208
Ages eligible for Study
Genders eligible for Study
Accepts Healthy Volunteers
Patients ≥ 18 years of age who meet the diagnosis of EER seizure, and previously they have been treated according to the clinical protocol at our center status (Diazepam 10mg Clonazepam 1mg and Phenytoin or iv at a dose of 20mg/kg in case persistence of the clinic):
Present seizures for at least 30 minutes without regaining awareness among them.
Patients ≥ 18 years of age who meet the diagnosis of nonconvulsive EER, and previously they have been treated according to the clinical protocol at our center status
(Diazepam 10mg Clonazepam 1mg and Phenytoin or iv at a dose of 20mg/kg in case persistence of the clinic):
After submitting an EER seizures that yield clinically performed an EEG that shows SE electricity.
Evidence of a non-convulsive SE to perform an EEG of a patient admitted for any cause, either by filing seizures, altered mental status, or any other cause, and to persist after the treatment administered previously discussed.
Patients in whom it has obtained the written informed consent by the representative and/or patient, as the case
Patients with severe cerebral anoxia, when the first EEG evidences a pattern of flare-suppression.
Patients who registers PLEDs (periodic epileptic lateralaized Discharges) without clinical seizure activity association to register or without electrical crises.
Patients < 18 years of age.
Patients in whom there is diagnostic doubt (eg non-convulsive status among and encephalopathy).
Pregnant or breastfeeding.
Patients with allergy to phenytoin, hydantoin or hypersensitivity to sodium valproate
Patients with porphyria
Patients with severe liver disease or dysfunction.
Patients with heart block or second and third grade sinus bradycardia.
All locations for NCT01586208
Hospital Universitari de Bellvitge
L'Hospitalet de Llobregat, Barcelona, Spain, 08907
View full eligibility
Tris trial is registered with FDA with number: NCT01586208. The sponsor of the trial is Hospital Universitari de Bellvitge and it is looking for 5 volunteers for the current phase.
Official trial title: Refractory Status Epilepticus: Plasmatic Levels Monitorization Utility
1What's a trial
4Get in touch
What's a trial
Not sure you're well informed about clinical trials? Learn more about their benefits, risks and other important details.
Enter your details like condition, age, gender and other preferences and we will show you a list of all relevant clinical trials.
Review the summary of the selected clinical trial and all the locations near you in order to see if it's of interest to you.
Get in touch
You've found an interesting trial? We'll need a bit more information about you so we can connect you to the doctor in charge.
Some people want to consult their doctor before considering participation in a clinical trial. This is absolutely normal as your doctor should know your medical history and should be able to advise you. If you want you can easily share the information for this trial with your doctor by clicking on the button below.